| Beova (vibegron) / Merck (MSD), Kissei, Kyorin, Sumitomo Pharma, Pierre Fabre |
BEST, NCT05806164: Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence |
|
|
| Recruiting | 4 | 432 | US | Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox], Botox | Women and Infants Hospital of Rhode Island, University of New Mexico, University of Alabama at Birmingham, University of California, San Diego, Howard University, Brown University, Patient-Centered Outcomes Research Institute | Urgency Urinary Incontinence | 07/26 | 07/27 | | |
2018-003136-72: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
|
|
| Not yet recruiting | 3 | 300 | Europe | Vibegron, URO-901, RVT-901, Film-coated tablet | Urovant Sciences GmbH, Urovant Sciences GmbH | Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT03902080: Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
|
|
| Completed | 3 | 1105 | Europe, Canada, US | Vibegron, RVT-901, MK-4618, KRP-114V, URO-901, Placebo | Urovant Sciences GmbH | Overactive Bladder | 06/23 | 06/23 | | |
2018-003135-30: Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptoms |
|
|
| Not yet recruiting | 3 | 1088 | Europe | Vibegron, URO-901, RVT-901, Film-coated tablet | Urovant Sciences GmbH, Urovant Sciences GmbH | Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23] | | | | |
| Recruiting | 2/3 | 85 | US | Vibegron | Urovant Sciences GmbH, Urovant Sciences GmbH | Neurogenic Detrusor Overactivity | 01/27 | 09/27 | | |
| Not yet recruiting | 1 | 75 | NA | Placebo, Propranolol, Gemtesa | University of Missouri-Columbia | Aging, Menopause, Hypoxia, Vasodilation | 07/25 | 07/25 | | |
NCT05067478: Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB) |
|
|
| Active, not recruiting | N/A | 400 | US | Vibegron, GEMTESA | Urovant Sciences GmbH | Overactive Bladder | 07/24 | 09/24 | | |
NCT06438861: Role of Combination Therapy in Women With Refractory Overactive Bladder |
|
|
| Not yet recruiting | N/A | 54 | NA | Vibegron 75mg, Placebo | University of Alabama at Birmingham | Overactive Bladder Syndrome | 10/25 | 01/26 | | |
| nesuparib (JPI-547) / Jeil |
NCT05475184: A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor |
|
|
| Not yet recruiting | 2 | 58 | NA | JPI-547 | Onconic Therapeutics Inc. | Ovarian Cancer | 11/24 | 06/25 | | |
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer |
|
|
| Not yet recruiting | 1 | 24 | NA | JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel | Onconic Therapeutics Inc. | Pancreatic Ductal Adenocarcinoma | 08/23 | 08/23 | | |
| Jaqbo (zastaprazan) / Jeil |
NCT05443984: JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis |
|
|
| Recruiting | 3 | 298 | RoW | JP-1366 20mg, Esomeprazole 40mg | Onconic Therapeutics Inc. | Erosive Esophagitis | 08/22 | 10/22 | | |
NCT05448001: Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer |
|
|
| Not yet recruiting | 3 | 328 | NA | JP-1366 20mg, Lansoprazole 30mg | Onconic Therapeutics Inc. | Gastric Ulcer | 10/23 | 12/23 | | |
NCT06439563: Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers |
|
|
| Not yet recruiting | 3 | 364 | RoW | JP-1366 10 mg, Lanston Capsule 15 mg, JP-1366 10 mg placebo, Lanston Capsule 15 mg placebo | Onconic Therapeutics Inc. | Peptic Ulcer | 08/27 | 12/27 | | |
NCT05814809: Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers |
|
|
| Completed | 1 | 30 | RoW | JP-1366 20mg tablet, Zastaprazan 20mg, JP-1366 20mg capsule | Onconic Therapeutics Inc. | Healthy | 10/22 | 11/22 | | |
NCT05712681: Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 24 | RoW | JP-1366 20mg tablet | Onconic Therapeutics Inc. | Healthy | 04/23 | 05/23 | | |
| dapagliflozin/olmesartan medoxomil (ATB-101) / Autotelic, Jeil |
NCT05573477: Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes |
|
|
| Recruiting | 3 | 248 | RoW | ATB-1011, ATB-1012, ATB-1013, ATB-1011 placebo, ATB-1012 placebo, ATB-1013 placebo | Autotelicbio | Essential Hypertension, Diabetes Mellitus, Type 2 | 01/24 | 06/24 | | |
